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The enormous economic and societal burdens associated with chronic wounds suggest a critical need for new
approaches to manipulate the wound microenvironment to support improved repair and prevent secondary
complications. The main factors that lead to chronic wounds are the lack of growth factors to stimulate cellular
healing responses, as well as the concomitant occurrence of wound infections that cause prolonged
inflammation. Current treatments include wound dressings, topical application of growth factors or antibiotics,
and various combination therapies that increase the accessibility of growth factors while eradicating
microorganisms in the wound bed. However, the harsh wound environment often clears topically administered
therapeutics from the wound, which reduces the local concentration of therapeutics and thus their effectiveness.
The overall objective of our work is to improve the efficacy of topically administered therapeutics using peptidemediated interactions between nanocarriers and matrices. We specifically utilize collagen mimetic peptides
(CMP) to tether nanostructure carriers onto collagen-containing matrices through the strand invasion of CMPs
into native collagen, resulting in control over the delivery of the cargo in response to cell-mediated collagen
degradation.
Our studies have revealed that in general, nanocarriers modified with CMPs enable extended control of cargo
release. Nanoparticles comprising EMP-CMP (Elastin-Mimetic Peptide and Collagen-Mimetic Peptide)
conjugates facilitated the controlled, zero-order release of the antibiotic vancomycin, compared to the first-order
release of vancomycin by a commonly used, liposomal drug nanocarrier. Furthermore, nanocarriers with CMP
modification could be sequestered in collagen containing matrices to a greater extent than nanocarriers without
CMP modification. As a result, the CMP-modified nanocarriers showed sustained release profiles. Also, CMP
modification of polyethyleneimine (PEI)/DNA nanocomplexes, when sequestered within collagen-containing
matrices, enhanced overall gene expression for at least 7 days.
Additionally, our studies have demonstrated that the controlled delivery of therapeutics driven by CMP
modification can also control their spatiotemporal action in vitro. The delivery of vascular endothelial growth
factor (VEGF)-A via the use of CMP-modified PEI/DNA in collagen-containing matrices enhanced cellular
signaling; murine fibroblasts differentiated to pro-healing myofibroblasts for at least 7 days and murine
endothelial cells formed complete tubular networks with significantly greater volume and larger diameter than
matrices lacking the CMP modification. Moreover, the delivery of vancomycin using EMP-CMP-nanoparticles
tethered in collagen-containing matrices improved the half-life of vancomycin activity, resulting in the prevention
of growth of methicillin-resistant Staphylococcus aureus (MRSA). Therefore, CMP modification of nanocarriers
enables not only the controlled release of therapeutics from collagen-containing matrices through CMP retention
within collagen, but also modulation of the bioactivities of therapeutics in vitro. Future work will include in vivo
excisional wound studies to evaluate the efficacy of therapeutics, delivered by CMP-tethered nanocarriers, on
wound healing, and evaluation of the platform for tissue regeneration applications.
Figure - Schematic representation of
collagen-mimetic peptide (CMP)-modified
nanocarriers tethered to collagen-based
matrices (Created with Biorender.com).

